Estrogen Blockers Market is Estimated to Witness High Growth Owing to Increasing Incidence of Breast

Gauricmi

Right Now

Estrogen Blockers Market is Estimated to Witness High Growth Owing to
Increasing Incidence of Breast Cancer

Estrogen blockers, also known as antiestrogens, are a class of pharmaceutical
drugs used primarily in the treatment and prevention of breast cancer in
hormone receptor-positive women. They work by blocking the effects of estrogen
in the body. Some common estrogen blockers include tamoxifen, raloxifene, and
aromatase inhibitors such as anastrozole, letrozole, and exemestane. These
drugs are commonly prescribed as adjuvant therapy for 5-10 years following
primary treatment of breast cancer or as preventative therapy for high-risk
women to reduce the chance of developing breast cancer. The rising incidence
and prevalence of breast cancer globally have resulted in a surge in demand for
effective estrogen blocking therapies. According to the Global Cancer
Observatory, 2.3 million new cases of breast cancer were diagnosed worldwide in
2020, accounting for nearly 12% of all new cancer cases.

The global
Estrogen Blockers Market is estimated to be valued at US$ 15.02 Billion in 2023
and is expected to exhibit a CAGR of
5.9% over the forecast period 2023 to 2030, as highlighted in a new report
published by Coherent Market Insights.

Market Dynamics:

Increasing incidence of breast cancer is one of the primary drivers boosting
the estrogen blockers market. As outlined earlier, breast cancer is one of the
most commonly occurring cancers globally. According to WHO, nearly 627,000
women died from breast cancer in 2020, making it the leading cause of cancer
death among women. As more women are getting diagnosed with breast cancer each
year, the demand for effective treatments such as estrogen blockers will
continue rising over the forecast period. Furthermore, rising awareness about
therapeutic and preventive benefits of estrogen blockers, especially among
high-risk women, is another driver fueling market growth. However, factors like
side effects associated with estrogen blockers like hot flashes, changes in
menstrual periods, leg cramps, osteoporosis, and cardiovascular problems could
hamper the market to an extent.

SWOT Analysis

Strength: Estrogen blockers help to reverse the effects of excess estrogen in
the body. They block the estrogen receptors and prevent estrogen from binding
and stimulating cell growth. Some estrogen blockers have been found to reduce
breast cancer recurrence rates in postmenopausal women by as much as 50% with
few side effects.

Weakness: Estrogen blockers could cause menopausal-like side effects like hot
flashes, night sweats, and vaginal dryness in some women. Additionally, long
term safety of estrogen blockers is still being studied as they have only been
approved for clinical use since the late 1990s.

Opportunity: Rising number of postmenopausal women and growing awareness about
managing health risks of estrogen open up opportunities for estrogen blockers
market. Developing new delivery methods and combining estrogen blockers with
other drugs can further boost the market.

Threats: Strict regulations for approval of new cancer drugs and potential
safety issues discovered during long term use studies can negatively impact the
estrogen blockers market. Patent expiries of major drugs will increase
competition from generic manufacturers.

Key Takeaways

Global
Estrogen Blockers Market Size is expected to witness high growth over
the forecast period of 2023 to 2030. The global Estrogen Blockers Market is
estimated to be valued at US$ 15.02
Billion in 2023 and is expected to
exhibit a CAGR of 5.9% over the
forecast period 2023 to 2030.

North
America currently dominates the market owing to high incidence of breast cancer
and increasing healthcare spending in the region. Rising focus on increasing
research and development activities for innovating advanced treatment options
to manage breast cancer will propel the North American estrogen blockers
market. Europe holds the second largest share of the estrogen blockers market
and is expected to grow at a steady pace during the forecast period. Increasing
initiatives by governments and non-profit organizations to spread awareness
about breast cancer and its prevention and treatment in countries like Germany,
United Kingdom and France contribute to the robust market size.

Key players operating in the estrogen blockers market are Pfizer, AstraZeneca,
Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Hikma
Pharmaceuticals PLC, Accord Healthcare Ltd., Mylan N.V. and Sun Pharmaceutical
Industries Ltd. Patent expiry of major drugs like tamoxifen has boosted the
availability of low-cost generic versions. However, key players are focused on
developing advanced formulations and therapeutic combinations to stay ahead of
competition.